ArticleLupus science & medicine2025
Dyspigmentation and scarring in cutaneous lupus erythematosus.
Article in Lupus science & medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
objectiveNo studies have investigated the incidence and correlation of scarring and dyspigmentation across all cutaneous lupus erythematosus (CLE) categories and subtypes. As better characterisation of such symptoms may impact how clinicians document disease damage as well as manage patients' expectations on their disease course, we set out to investigate the relationship between dyspigmentation and scarring in CLE further.
methodsWe conducted a cross-sectional review of our IRB-approved CLE database at the University of Pennsylvania. Patients were divided by category and chronic CLE (CCLE) subtype. Dyspigmentation and scarring were quantified using the CLE Disease Area and Severity Index damage score. Data on dyspigmentation and scarring were captured from the patient visit where dyspigmentation was highest.
resultsDyspigmentation and scarring significantly differed between CLE categories and CCLE subtypes. Across categories, CCLE had the highest medians for dyspigmentation and scarring. Across CCLE subtypes, discoid lupus erythematosus (DLE) had the highest medians for dyspigmentation and scarring. Positive correlations for dyspigmentation and scarring were seen in CCLE, DLE and LE panniculitis.
conclusionsDyspigmentation and scarring correlation differences highlight the importance of accurate assessment and documentation of both elements of damage as well as classification of CLE category and subtype. Our results reflect important differences in the CLE categories and CCLE subtypes which may be helpful for clinicians and patients as they navigate the course of the disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.